Breaking barriers With basal insulin biosimilars in type 2 diabetes.
Heller, Simon Raposo, João Filipe Tofé, Santiago Hanif, Wasim Schroner, Zbynek Down, Su Blevins, Thomas
Heller, Simon
Raposo, João Filipe
Tofé, Santiago
Hanif, Wasim
Schroner, Zbynek
Down, Su
Blevins, Thomas
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-08-09
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to greater access to basal insulin for vast populations. In this review, we discuss evidence demonstrating equipoise between basal insulin biosimilars and the patented analogs they may replace.
Citation
Heller S, Raposo JF, Tofé S, Hanif W, Schroner Z, Down S, Blevins T. Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes. Clin Diabetes. 2023 Spring;41(2):154-162. doi: 10.2337/cd22-0016. Epub 2023 Aug 9.
Type
Article